<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04980872</url>
  </required_header>
  <id_info>
    <org_study_id>7075-006</org_study_id>
    <secondary_id>MK-7075-006</secondary_id>
    <secondary_id>2021-001369-19</secondary_id>
    <nct_id>NCT04980872</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)</brief_title>
  <official_title>A Multicenter, Open-label, Phase 2, Extension Trial to Study the Long-term Safety in Participants With PROS or Proteus Syndrome Who Are Currently Being Treated With Miransertib in Other Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to&#xD;
      participants at least 2 years of age with Phosphatidylinositol-4,5-Bisphosphate 3-Kinase&#xD;
      Catalytic Subunit Alpha (PIK3CA)-related Overgrowth Spectrum (PROS) and Proteus Syndrome&#xD;
      (PS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2021</start_date>
  <completion_date type="Anticipated">August 29, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 29, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>None (Open-label)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing a Serious Adverse Event (SAE)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>An SAE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An SAE can therefore be any such event that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalizations, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is considered by the investigator to be an important medical event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study treatment due to an Adverse Event (AE)</measure>
    <time_frame>Up to approximately 4 years</time_frame>
    <description>An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product and does not imply any judgment about causality.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)</condition>
  <arm_group>
    <arm_group_label>Miransertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with either PROS or PS receive miransertib orally once daily between 5 and 35 mg/m^2 based on prior approved dosing for up to 48 cycles. A cycle is 28 days long.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miransertib</intervention_name>
    <description>Miransertib capsules administered orally either 1 hour before or 2 hours after a meal.</description>
    <arm_group_label>Miransertib</arm_group_label>
    <other_name>MK-7075</other_name>
    <other_name>ARQ 092</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has PROS or PS and is currently being actively treated with miransertib as part of&#xD;
             Study MK-7075-002 (NCT03094832) or ArQule's Compassionate Use and Extended Access&#xD;
             Program (CU/EAP, NCT03317366)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has previously discontinued miransertib due to related SAEs or other intolerance of&#xD;
             miransertib&#xD;
&#xD;
          -  Received other investigational agents, if any, that were administered between leaving&#xD;
             Study MK-7075-02 or ArQule's CU/EAP and entering this trial&#xD;
&#xD;
          -  Receives inhibitors of the mechanistic target of rapamycin (mTOR) pathway (eg,&#xD;
             sirolimus, everolimus)&#xD;
&#xD;
          -  Receives immunosuppressive therapies&#xD;
&#xD;
          -  Receives continuous high dose steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seattle Children's Hospital ( Site 0103)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>206-987-1927</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital ( Site 0203)</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61249853100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bundaberg Base Hospital ( Site 0202)</name>
      <address>
        <city>Bundaberg</city>
        <state>Queensland</state>
        <zip>4670</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61741502222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Ges√π-Centro Trials ( Site 0087)</name>
      <address>
        <city>Rome</city>
        <state>Roma</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390668593642</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ARQ 092</keyword>
  <keyword>ArQule</keyword>
  <keyword>AKT</keyword>
  <keyword>mTOR</keyword>
  <keyword>PIK3CA</keyword>
  <keyword>PROS</keyword>
  <keyword>Proteus</keyword>
  <keyword>Overgrowth</keyword>
  <keyword>Congenital malformations</keyword>
  <keyword>MOSAIC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteus Infections</mesh_term>
    <mesh_term>Proteus Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

